Frequently Asked Questions
What does your company do?
Vincere is developing drugs that can restore mitochondrial quality to slow the progression of Parkinson’s disease and other age-related disorders where deficits in mitochondrial health is known to underlie the disease process.
Where will your company be in 3 years?
We aim to have at least one molecule ready for clinical trials and others in late stage preclinical development within 3 years.
How did you choose your molecular targets?
Using our patented biology simulation platform that integrates large scale human genomic and biochemical data, we identified disease-associated mechanisms and molecular targets.
The lead targets, parkin and USP30, were selected to take advantage of the recently solved, high resolution crystal structures, which enable rational drug design.
What differentiates you from your peers?
In the realm of start-up biopharmaceutical firms, we are uniquely positioned to take advantage of our computational capabilities to inform biological hypotheses and medicinal chemistry to efficiently progress multiple targets and discovery programs.
What are the biggest risks and what are you doing to circumvent the same?
Science risk - There are challenges inherent to development of therapeutics for brain disorders. With a platform-based approach and a computational biology-informed target engine, we are minimizing the risk of failure.
Execution risk - While execution risks are inevitable, we have assembled an experienced and passionate internal team and external partners and advisors to deliver our strategic goals.
Funding/Partnership risk - Additional capital required to deliver clinical candidates may not be available when/as needed. Through strategic outreach to traditional and corporate VCs and pharmaceutical companies we have built a network of informed and interested parties.